Some links on our site may earn us a commission at no extra cost to you. Learn more.
Updated August 2026: Retitled and restructured around a criteria-first comparison in place of the old brand-listing face-off format, added an itemized monthly-cost table, and re-verified every price and regulatory claim below against current sources as of August 2026.
Medical disclaimer: We are not doctors or medical professionals, and this comparison is not medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider and are not appropriate for everyone. Consult a qualified clinician before starting any medication or weight loss program.
Start with the fact that gets blurred most often in this category: only brand-name Wegovy and Zepbound are FDA-approved. Compounded semaglutide and tirzepatide — the entire SkinnyRx lineup — are not, and the FDA’s own guidance says so directly. That distinction, more than price or format, is the criterion that should decide which side of this comparison fits a given buyer, which is why the criteria below come before any scoring.
The Four Criteria That Actually Decide This
Before scoring Hims against SkinnyRx, it helps to be precise about what actually separates a brand-name GLP-1 program from a compounded one — because marketing language on both sides tends to blur exactly these lines.
- Regulatory status. Whether the medication itself went through FDA premarket review, or is a compounded formulation that hasn’t.
- Active ingredient sourcing. Whether the semaglutide or tirzepatide comes through the branded manufacturer’s own FDA-inspected supply chain, or from a compounding pharmacy formulating it to a prescription.
- Monthly cost, itemized. Not the headline number — the consultation or membership fee, the medication charge, and shipping, itemized separately so nothing hides inside a bundle.
- Medical oversight model. How much clinical contact patients actually get: intake-only messaging, versus something closer to ongoing monitoring.
How Hims and SkinnyRx Score on Each Criterion
Regulatory status: Hims dispenses the Wegovy pen and Wegovy pill, both FDA-approved formulations of semaglutide, sold following Hims’ 2026 settlement with Novo Nordisk. SkinnyRx’s semaglutide and tirzepatide are compounded — formulated by a compounding pharmacy rather than manufactured and approved as a finished drug product. The FDA’s shortage declarations that had allowed broader compounding under Sections 503A and 503B both ended in 2025 — semaglutide’s grace periods closed in April and May 2025, tirzepatide’s in February and March 2025 — after which large-scale compounding of essentially-copy versions became restricted to cases with documented patient-specific need.
Active ingredient sourcing: Hims’ brand-name pathway runs through Novo Nordisk’s own FDA-inspected manufacturing. SkinnyRx sources its active ingredient through licensed U.S. compounding pharmacies and ships from what it describes as FDA-regulated pharmacies — a real regulatory category (pharmacies are FDA-registered and state-licensed), but distinct from the drug product itself carrying FDA approval.
Monthly cost: broken out in full below.
Medical oversight model: both platforms run on asynchronous telehealth — an online intake reviewed by a licensed prescriber, with ongoing contact handled through messaging rather than scheduled visits or lab work. Neither is built for complex medical histories; both are designed for straightforward cases where the intake form covers what a prescriber needs to know.
The Itemized Monthly Cost, Tier by Tier
Neither platform’s headline price is the whole bill. Below is each real monthly cost broken into its parts — membership or consultation, medication, and shipping — as published on each program’s own site and checked in August 2026.
| Program & Tier | Membership / Consultation | Medication | Shipping | Total Monthly (uninsured) |
|---|---|---|---|---|
| Hims — Wegovy pen, self-pay | $149/mo (after a $39 first month) | Starting at $199/mo, billed separately | Not separately itemized | ~$348/mo and up |
| Hims — insured + NovoCare savings card | $149/mo membership still applies | As low as $0–$25/mo for eligible commercially insured patients | Not separately itemized | ~$149–$174/mo |
| SkinnyRx — compounded semaglutide (injectable/sublingual) | Included, no separate fee | $199/mo | Free overnight | $199/mo |
| SkinnyRx — compounded semaglutide (tablets) | Included, no separate fee | $249/mo | Free overnight | $249/mo |
| SkinnyRx — compounded tirzepatide | Included, no separate fee | $299/mo | Free overnight | $299/mo |
Hims figures come from the Wegovy pen and membership pages at hims.com, checked August 2026; SkinnyRx figures come from SkinnyRx’s own published pricing, checked the same month. On a per-dose basis, assuming the standard once-weekly injection schedule most GLP-1 prescribers use, the uninsured Hims total works out to roughly $80/week and the SkinnyRx injectable tier to about $46/week, before either program’s dose increases (which typically raise the medication line). Sublingual and tablet formats may follow a different dosing cadence set by the prescribing clinician, so treat the weekly figure as an injectable-to-injectable comparison only.
The Regulatory Line You Shouldn’t Blur
“Not FDA-approved” doesn’t mean illegal or automatically unsafe — compounding is a legal, regulated practice, and pharmacies compounding these drugs are FDA-registered and state-licensed. It does mean the finished product hasn’t gone through the FDA’s own review of a specific formulation’s safety, effectiveness, and manufacturing consistency, which is what “FDA-approved” actually certifies. In February 2026 the FDA sent a warning letter to Lean Rx, Inc., dba SkinnyRx, over specific marketing language — including claims that its product contained “the same active ingredient as name-brand GLP-1 medications” and “the same active ingredient as FDA-approved medications” — that the agency said falsely implied FDA approval the compounded product doesn’t have. The FDA also flagged SkinnyRx’s own name appearing on product labels when SkinnyRx was not the actual compounder. This was a labeling and marketing violation, not a finding about manufacturing safety, but it’s a direct, on-the-record example of exactly the line this criterion is about. Physicians have raised similar concerns more broadly: a Stanford Medicine report describes clinician worries about inconsistent dosing and sourcing across compounding pharmacies industry-wide, not specific to any one program.
Where Insurance Changes Everything
Wegovy’s retail list price is $1,349/month without insurance. Almost nobody choosing Hims pays that: the platform’s own self-pay pricing starts at $199/month for the medication, and Novo Nordisk’s NovoCare savings card can bring the cost to $0–$25/month for patients with qualifying commercial insurance coverage. That makes insurance status the single biggest swing factor in this comparison — a compounded program can’t currently match a $0–$25/month insured price, but a self-pay patient comparing $348+/month against SkinnyRx’s $199–$299/month is looking at compounded medication being the cheaper option before the regulatory question is weighed in.
Fine Print Worth Reading Before Checkout
Hims’ membership bills separately from medication, auto-renews, and does not guarantee a prescription — factor the $149/month in even for a month a prescriber declines to renew a script. SkinnyRx bundles the consultation into its flat monthly price and carries no membership fee, but some customers have reported billing that ran on a different cadence than expected. Read the billing terms on each program’s own checkout page before entering payment information, on either platform.
Who Each Approach Fits
Someone who wants an FDA-approved formulation and can access commercial insurance plus a manufacturer savings card is the clearest fit for the brand-name path — the price at that combination beats every compounded option here. Someone paying entirely out of pocket, wanting a needle-free format, or prioritizing the lowest verified monthly number is the clearest fit for a compounded program, provided they’ve read and accepted what “not FDA-approved” means for the specific product they’d be taking. Neither profile fits someone who hasn’t yet had the one conversation that actually matters: with a licensed healthcare provider, about whether a GLP-1 medication is appropriate for their health history at all.
How We Compared
Every price and regulatory claim above was checked in August 2026 against each program’s own published pricing pages and the FDA’s own guidance and warning-letter record on compounded GLP-1 medications, named in-sentence by source. We did not test either program’s medication or clinical process ourselves — this is a cost and regulatory-status comparison, not a clinical review. Read more about how we source and vet claims on our editorial standards page.
Prices are approximate, current as of publication, and change frequently — confirm the latest price with the provider before enrolling.
Published July 12, 2026. Updated August 2026.
Related GLP-1 Comparisons
- Shopping the wider field? Our four-program audit of TrimRX, Brightmeds, Wellorithm, and AltRx checks prescriber licensing and pharmacy transparency across each one.
- For the full itemized year-one math on compounded versus brand-name, see the GLP-1 monthly bill, itemized.
Wegovy®, Ozempic®, Zepbound®, and Mounjaro® are trademarks of their respective owners, which are not affiliated with this site. One market note: Eden, another frequently searched program, paused new-patient GLP-1 enrollment as of mid-2026.
Frequently Asked Questions
Is compounded semaglutide or tirzepatide FDA-approved?
No. Only the brand-name products — Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro — go through the FDA’s premarket review process. Compounded versions, including everything SkinnyRx sells, are not FDA-approved; the FDA’s own guidance states directly that compounded drugs are not approved by the FDA.
How much does a Hims GLP-1 prescription actually cost per month?
After the $39 first month, the Hims Weight Loss Membership renews at $149/month, billed separately from medication. Hims lists the Wegovy pen starting at $199/month for eligible self-pay patients, which puts an uninsured floor around $348/month before any dose increase. Commercially insured patients combining coverage with Novo Nordisk’s savings card can pay as little as $0–$25/month for the medication itself.
What does SkinnyRx charge each month?
SkinnyRx publishes three tiers: compounded semaglutide injectable or sublingual at $199/month, semaglutide tablets at $249/month, and compounded tirzepatide at $299/month — each including the consultation and free overnight shipping, with no separate membership fee.
Why did the FDA send SkinnyRx’s operator a warning letter?
In February 2026 the FDA sent a warning letter to Lean Rx, Inc., dba SkinnyRx, over marketing language — including claims implying the same active ingredient as FDA-approved brand-name drugs — that the agency said blurred the line around a product that is not itself FDA-approved. The FDA described it as a labeling-claims issue, not a manufacturing-safety finding.
Do I need to see a doctor before starting either program?
Yes. Both platforms use asynchronous telehealth intake reviewed by a licensed prescriber, but neither replaces a conversation with your own healthcare provider about whether a GLP-1 medication is appropriate for your health history. This article is not medical advice.
